Adalta Ltd. · ASX:1AD
Adalta — Biotech Showcase 2022 Virtual conference
26 slides from Adalta's conference presentation, Jan 4, 2022
Slide 1: AdAlta presenting at January biotech conferences
4 January 2022 ASX Announcement ADALTA PRESENTING AT JANUARY BIOTECH CONFERENCES For personal use only MELBOURNE Australia, 4 January 2022: AdAlta Limited (ASX:1AD), the clinical stage drug discovery company developing novel therapeutic products from its i-body platform is participating virtually at
Slide 2: About AdAlta and Biotech Showcase
The i-body technology mimics the shape and stability of a unique and versatile antigen binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with pr
Slide 3: For more information, please contact
For more information, please contact: Investors Media Tim Oldham, CEO & Managing Director IR Department For personal use only Tel: +61 403 446 665 Tel: +61 411 117 774 E: [email protected] E: [email protected]
Slide 4: Corporate overview
For personal use only Corporate overview December 2021
Slide 5: AdAlta today
INVESTOR PRESENTATION – DECEMBER 2021 3 AdAlta today AdAlta is building significant growth momentum while retaining agility to respond and adapt to data and opportunities For personal use only • i-body platform: can create therapeutics addressing targets underserved by traditional antibodies • Fibro
Slide 6: Four human health needs AdAlta is addressing today
INVESTOR PRESENTATION – DECEMBER 2021 4 Four human health needs AdAlta is addressing today For personal use only Antibodies cannot do everything! AdAlta’s i-bodies are a new drug discovery platforms for challenging targets Idiopathic Pulmonary Fibrosis: degenerative, fatal AdAlta’s AD-214 could meet
Slide 7: What is the i-body advantage?
INVESTOR PRESENTATION – DECEMBER 2021 5 What is the i-body advantage? All the selectivity and specificity of antibodies with greater versatility and tunability For personal use only Small size, flexible binding domain Confers unique binding capability for targets challenging traditional Accessing an
Slide 8: An immensely powerful drug discovery platform
INVESTOR PRESENTATION – DECEMBER 2021 6 An immensely powerful drug discovery platform i-body technology can enable a wide range of therapeutic and diagnostic products For personal use only Wide range of target classes Wide range of product formats CAR-T Targeting agents Bi-specifics and Chemokine mu
Slide 9: AD-214: first in class treatment for fibrosis
INVESTOR PRESENTATION – DECEMBER 2021 7 AD-214: first in class treatment for fibrosis AD-214’s initial focus is IPF For personal use only CXCR4 First-in-class (novel mode Human of action) treatment Lung Tissue Brown stain shows increased amount of Targets a receptor called CXCR4 in fibrotic CXCR4 lu
Slide 10: AD-214: multiple indication extension options
INVESTOR PRESENTATION – DECEMBER 2021 8 AD-214: multiple indication extension options For personal use only Each additional indication could address multiple markets with US$ billion potential Data in tissue and animal models show that AD-214 may improve fibrosis across a range of fibrotic diseases
Slide 11: Idiopathic Pulmonary Fibrosis (IPF)
INVESTOR PRESENTATION – DECEMBER 2021 4 Idiopathic Pulmonary Fibrosis (IPF) AdAlta’s first target, already a $3b market, is a degenerative, fatal disease in dire need of improved treatment options: For personal use only i-bodies have been designed to target a novel mode of action to address this med
Slide 12: Phase I clinical and PET imaging inform dosing and route of administration
INVESTOR PRESENTATION – DECEMBER 2021 10 Phase I clinical and PET imaging inform dosing and route of administration Intravenous AD-214 is well tolerated in Phase I studies; PET imaging with radiolabelled AD-214 supports early transition to inhaled route For personal use only of administration Phase
Slide 13: Predicted regional deposition of AD-214 in human lungs
INVESTOR PRESENTATION – DECEMBER 2021 11 Predicted regional deposition of AD-214 in human lungs The ICRP661 model predicts that 17-46% of AD-214 delivered from commercial nebulisers will be delivered to the smallest For personal use only (alveolar/interstitial) airways of the lungs where most IPF is
Slide 14: IPF partnering: valuable options as early as Phase I
INVESTOR PRESENTATION – DECEMBER 2021 12 IPF partnering: valuable options as early as Phase I For personal use only IPF assets have recently yielded attractive deal terms at early stages of development Date Licensee Licensor Transaction Terms Asset/Mode of Action Clinical Phase Additional Comments S
Slide 15: Immuno-oncology (I/O) PET imaging
INVESTOR PRESENTATION – DECEMBER 2021 13 Immuno-oncology (I/O) PET imaging For personal use only US$6.4b PET imaging market: could help identify the 20-40% of patients who will respond to revolutionary I/O drugs faster Immuno-oncology (I/O) drugs US$95 billion I/O market1 reactivate the patient’s ow
Slide 16: GZMB i-body asset: GE Healthcare co-development collaboration
INVESTOR PRESENTATION – DECEMBER 2021 14 GZMB i-body asset: GE Healthcare co-development collaboration Second asset in pre-clinical development; and could generate royalty revenue sooner than a therapeutic due to shorter diagnostic For personal use only development timelines Pipeline asset generatin
Slide 17: CAR-T therapies are revolutionising cancer treatment
INVESTOR PRESENTATION – DECEMBER 2021 15 CAR-T therapies are revolutionising cancer treatment For personal use only Reprogramming a patient’s own immune system to fight cancer is a fast-growing market at the cutting edge of medicine earned by CAR-T therapy step 1 CAR engineered chemokine >US$1b prod
Slide 18: i-body enabled CAR-T assets: Carina collaboration
INVESTOR PRESENTATION – DECEMBER 2021 16 i-body enabled CAR-T assets: Carina collaboration For personal use only Third program entering discovery to generate precision engineered CAR-T products, providing new hope for patients with cancer World-leading proprietary CAR-T technologies for superior acc
Slide 19: Building the first iCAR-T cell therapy: proof of principle results
INVESTOR PRESENTATION – DECEMBER 2021 17 Building the first iCAR-T cell therapy: proof of principle results For personal use only i-body enabled CAR-T (iCAR-T) cells have been successfully generated by Carina and demonstrate in vitro cell killing (lysis)1 Experimental details • LOVO and LIM1215 are
Slide 20: AdAlta assets and business model
INVESTOR PRESENTATION – DECEMBER 2021 18 AdAlta assets and business model AdAlta’s pipeline is expanding to plan. The i-body platform is creating wholly owned or co-developed assets. Our team is For personal use only building skills in fibrosis/inflammation and immuno-oncology. Co- Precision enginee
Slide 21: The potential of our strategy: Ablynx case study
INVESTOR PRESENTATION – DECEMBER 2021 19 The potential of our strategy: Ablynx case study Multiple internal and external assets drive value, attract partners For personal use only GPCR platform exits Acquisition US$5B Feb-15 acquired by Sosei IPO Phase Ib + 7 preclinical leads US$182m US$400m +US$83
Slide 22: Calendar 2022 goals
INVESTOR PRESENTATION – DECEMBER 2021 20 Calendar 2022 goals For personal use only Significant progress anticipated on both existing core programs and further pipeline expansion AD-214 – first in class anti-fibrotic • Inhaled formulation development: nebulisation feasibility, efficacy in animal mode
Slide 23: Industry experienced leadership and advisors
INVESTOR PRESENTATION – DECEMBER 2021 21 Industry experienced leadership and advisors For personal use only Team with experience from discovery through manufacturing, clinical and commercialisation Board Executive Scientific Advisory Board Dr Paul MacLeman Tim Oldham, PhD Brian Richardson Chair CEO
Slide 24: Corporate snapshot
INVESTOR PRESENTATION – DECEMBER 2021 22 Corporate snapshot For personal use only Key financial details (22 Dec 2021) Share price performance (last 12 months) ASX code 1AD 0.25 7.0 Market capitalisation A$24.32m 6.0 0.20 Share price (12 month closing range) A$0.082 ($0.074 - 0.195) 5.0 12 month retu
Slide 25: Partner and investor proposition
INVESTOR PRESENTATION – DECEMBER 2021 23 Partner and investor proposition For personal use only Fibrosis/inflammation Immuno-oncology Lead asset advancing to Phase II 2 x co-development collaborations to Powerful i-body discovery platform >$3b market potential in first indication1 leverage platform
Slide 26: Contact
For personal use only Contact: Tim Oldham, CEO and Managing Director [email protected] www.adalta.com.au